Publications by authors named "Jacob Stroh"
Patients with hematologic malignancies still face a significant risk of severe coronavirus disease 2019 (COVID-19). The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-neutralizing monoclonal antibody combination tixagevimab/cilgavimab (TIX/CGB) could be administered to immunocompromised patients for pre-exposure prophylaxis (PrEP) before the emergence of TIX/CGB-resistant COVID-19 Omicron variants. TIX/CGB application could be carried out regardless of the host's immune response to previous active SARS-CoV-2 vaccinations or infections.
View Article and Find Full Text PDFArticle Synopsis
- The DNA damage response (DDR) is important for preventing cancer, but it doesn’t always work well in tumors, making it a target for new treatments.
- Researchers found that a protein called SLF2 helps the DDR and is linked to a type of blood cancer called B-cell lymphoma, especially in patients who might have a worse outcome.
- When SLF2 is missing, it causes more DNA damage in cancer cells, which can be treated with a special drug that targets another process called SUMOylation, making it a potential way to fight aggressive lymphoma.
Rationale: Multiple myeloma (MM) cells synthesize large amounts of paraproteins, making radiolabeled amino acids promising candidates for PET imaging of MM patients.
Methods: We compare tumor uptake of the two amino acid analogs [F]-fluoroethyltyrosine and [F]-FACBC in a MM xenograft model and show the feasibility of PET imaging with [F]-FACBC in a MM patient.
Results: Preclinically [F]-FACBC showed superior performance, mainly due to the uptake via the ASC-system.
Biomarkers that predict response to lenalidomide maintenance therapy in patients with multiple myeloma (MM) have remained elusive. We have shown that immunomodulatory drugs (IMiDs) exert anti-MM activity via destabilization of MCT1 and CD147. In this study, cell samples of 654 patients with MM who received lenalidomide (n = 455), thalidomide (n = 98), or bortezomib (n = 101) maintenance were assessed by gene expression profiling and RNA sequencing, followed by correlation of MCT1 and CD147 expression with data for progression-free survival (PFS) and overall survival (OS).
View Article and Find Full Text PDFThe complex architecture of transmembrane proteins requires quality control (QC) of folding, membrane positioning, and trafficking as prerequisites for cellular homeostasis and intercellular communication. However, it has remained unclear whether transmembrane protein-specific QC hubs exist. Here we identify cereblon (CRBN), the target of immunomodulatory drugs (IMiDs), as a co-chaperone that specifically determines chaperone activity of HSP90 toward transmembrane proteins by means of counteracting AHA1.
View Article and Find Full Text PDF